- BICYCLIC COMPOUNDS AS KINASE MODULATORS, METHODS AND USES THEREOF
-
The present disclosure relates to derivatives of bicyclic compounds and their uses in therapy. In particular, the present disclosure relates to derivatives of bicyclic compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent diseases and conditions such as cancer and in specific embodiments, hepatocellular carcinoma (HCC). The present disclosure also relates to methods of synthesizing these compounds.
- -
-
-
- Preparation method for cabozantinib degradation impurity without p-fluoroaniline
-
The invention discloses a preparation method for a cabozantinib degradation impurity without p-fluoroaniline. The method comprises the following steps: preparation of 4-chloro-6,7-dimethoxyquinoline;preparation of an intermediate 1; and preparation of p-f
- -
-
Paragraph 0017; 0024-0025; 0031-0032
(2020/09/09)
-
- Preparation method of impurities in synthesis of cabozantinib malate
-
Belonging to the field of chemical pharmacy, the invention discloses a preparation method of impurities in synthesis of cabozantinib malate. The impurities include KB-2-A, KB-A and SM-3-B. The invention also provides a preparation method of impurity KB-2-
- -
-
Paragraph 0108-0128
(2019/11/21)
-
- A synthesis method of card abundantly for nepal (by machine translation)
-
The present invention provides a card abundantly for nepal synthesis method, the method to 1, 1 - cyclopropyl dicarboxylic acid as the starting material, after the acylation with 4 - [(6, 7 - dimethoxy - 4 - quinolyl) oxy] aniline condensation, with 4 - f
- -
-
-
- A tyrosine kinase inhibitor and wherein the intermediate preparation method
-
The invention relates to a preparation method for a tyrosine kinase inhibitor and a midbody thereof. According to the method, a compound 1,1-cyclopropane dicarboxylic acid diester is taken as a raw material, and 1-((4-((6,7-dimethoxy quinoline-4-yl) oxy)
- -
-
Paragraph 0138; 0139; 0140
(2016/10/10)
-
- METHOD OF PREPARING FLUORINE-18 LABELED CABOZANTINIB AND ITS ANALOGS
-
The present invention relates to a method of preparing Cabozantinib (Cyclopropane- 1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylo]amide (4-fluoro- phenyl)amide) and 18F labeled Cabozantinib.
- -
-
-
- DOSING OF CABOZANTINIB FORMULATIONS
-
The invention relates to administration of various pharmaceutical formulations of N- (4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve des
- -
-
-
- METABOLITES OF N-(4-{[6,7-BIS(METHYLOXY)QUINOLIN-4-YL]OXY}PHENYL)-N'-(4-FLUOROPHENYL) CYCLOPROPANE-1,1-DICARBOXAMIDE
-
The invention relates to metabolites of cabozantinib (I) as well as uses thereof.
- -
-
-
- C-MET MODULATORS AND METHODS OF USE
-
The present invention provides compounds, which have activity for modulating protein kinase enzymatic activity and are potentially useful for modulating cellular activities such as, e.g., proliferation, differentiation, programmed cell death, migration and chemoinvasion. The present invention also provides compositions containing such compounds, and methods for producing and using such compounds and compositions.
- -
-
-
- C-MET MODULATORS AND METHODS OF USE
-
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
- -
-
Page/Page column 233
(2008/06/13)
-